Abstracts Archive - Page 1533 of 2425 - ACR Meeting Abstracts

Abstract Number: 1733 • 2016 ACR/ARHP Annual Meeting
Sustained Efficacy of Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis
Kim Papp¹, Alice B. Gottlieb², Catherine L. Shuler³, Russel T. Burge³, Gregory Cameron³, Lisa Kerr³ and Philip J Mease⁴, ¹K Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, ON, Canada, ²Tufts University School of Medicine, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: PsA, a chronic immune-mediated inflammatory disease, can be progressive and destructive, resulting in physical deformities, impaired function, decreased quality of life, and increased mortality.…
Abstract Number: 1734 • 2016 ACR/ARHP Annual Meeting
Apremilast Is Associated with Long-Term DAS-28 (CRP) Remission and Improvements in Skin Disease: Results from a Phase III Study in DMARD/Biologic-Experienced Active Psoriatic Arthritis Patients
Christopher J Edwards¹, Francisco J Blanco², Jeffrey J Crowley³, Melissa McIlraith⁴, Kamal Shah⁴, Nikolay Delev⁴, Lichen Teng⁴ and Charles A Birbara⁵, ¹University Hospital Southampton, Southampton, United Kingdom, ²INIBIC-Hospital Universitario A Coruña, Galicia, Spain, ³Bakersfield Dermatology, Bakersfield, CA, ⁴Celgene Corporation, Summit, NJ, ⁵University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Treatment goals for long-term control of skin and joint symptoms in active psoriatic arthritis (PsA) include clinically important changes in DAS-28 (CRP), achievement of…
Abstract Number: 1735 • 2016 ACR/ARHP Annual Meeting
Canadian Humira Post-Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (Complete-PsA): Interim Analysis
Majed Khraishi¹, Boulos Haraoui², Louis Bessette^3,4, Yatish Setty⁵, William G. Bensen⁶ and Valencia P. Remple^7,8, ¹Department of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada, ³Faculty of Medicine, Laval University, Quebec, QC, Canada, ⁴Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ⁵Grey Bruce Health Services, Owen Sound, ON, Canada, ⁶Department of Medicine, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷AbbVie Corporation, Montreal, QC, Canada, ⁸School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: COMPLETE-PsA is an ongoing observational study planning to enroll 670 psoriatic arthritis (PsA) patients (pts) from ~40 sites across Canada. Main objectives are to…
Abstract Number: 1736 • 2016 ACR/ARHP Annual Meeting
Efficacy of TNF Inhibitors in Axial Spondyloarthritis According to the Presence of Objective Signs of Inflammation: A Multicentric Retrospective Study
Celine Vidal¹, Cédric Lukas², Bernard Combe³, Francis Berenbaum⁴, Christian Jorgensen⁵, Jeremie Sellam⁶ and Jacques Morel⁷, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ³Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁴Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ⁵Inserm u844, Unite ImmunoRhumatologie Therapeutique, Montpellier, France, ⁶Rheumatology, Saint-Antoine Hospital, Paris, France, ⁷Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France
Background/Purpose: TNF inhibitors (TNFi) are effective treatment in radiographic and non-radiographic axial spondyloarthritis (r-axSpA and nr-axSpA). Nr-axSpA have lower response rate in case of absence…
Abstract Number: 1737 • 2016 ACR/ARHP Annual Meeting
Adherence to Subcutaneous Biological Therapies Among Inflammatory Arthropaty Patients from a University Hospital
Catalina Gómez-Arango¹, M. Luz García-Vivar¹, Montserrat Alonso-Diez², M. Milagros Alvarez-Lavin², Eva Galindez-Agirregoikoa³, Olaia Fernández-Berrizbeitia³, Esther Ruíz-Lucea¹, Juan María Blanco-Madrigal¹, Jose Francisco Garcia-Llorente¹, Lidia Estopiñán-Fortea³, Ignacio Torre-Salaberri⁴, Edurne Guerrero-Basterretxea³, Itziar Calvo-Zorrilla³, Amaia Bilbao-González⁵ and Natalia Rivera-García⁵, ¹Rheumatology, Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ²Pharmacy Department, Basurto University Hospital, Bilbao, Spain, ³Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ⁴Rheumaytology, Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ⁵Research Department, Basurto University Hospital, Bilbao, Spain
Background/Purpose: Rheumatic inflammatory arthropaties such as Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Spondyloarthrities (SpA) are chronic diseases that require adequate therapies, sometimes biological drugs,…
Abstract Number: 1738 • 2016 ACR/ARHP Annual Meeting
Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison
Peter Nash¹, Iain B McInnes², Philip J Mease³, Ernest H. Choy^4,5, Howard Thom⁶, Chrysostomos Kalyvas⁷, Kunal Gandhi⁸, Shephard Mpofu⁹ and Steffen Jugl⁹, ¹Department of Medicine, University of Queensland, Brisbane, QLD, Australia, ²University of Glasgow, Glasgow, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁵CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom, ⁶University of Bristol, Bristol, United Kingdom, ⁷MAPI Group, Houten, Netherlands, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) and adalimumab (ADA) are approved for the treatment of active PsA in adults with an inadequate response to conventional DMARDs. A head-to-head…
Abstract Number: 1739 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis As Assessed By Matching-Adjusted Indirect Comparison: An Analysis Based on All Pivotal Phase 3 Clinical Trial Data
Walter P Maksymowych¹, Vibeke Strand², Peter Nash³, Howard Thom⁴, Andreas Karabis⁵, Kunal Gandhi⁶, Brian Porter⁶ and Steffen Jugl⁷, ¹University of Alberta, Edmonton, AL, ²Stanford University School of Medicine, Palo Alto, CA, ³Department of Medicine, University of Queensland, Brisbane, QLD, Australia, ⁴University of Bristol, Bristol, United Kingdom, ⁵MAPI Group, Houten, Netherlands, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) and adalimumab (ADA) are approved for the treatment of patients with active AS. However, there are no head-to-head randomized controlled trials (RCTs)…
Abstract Number: 1740 • 2016 ACR/ARHP Annual Meeting
Long-Term Improvements in Physical Function of DMARD-Naive and DMARD/Biologic-Experienced Psoriatic Arthritis Patients Treated with Apremilast: Data from a Large Database of 4 Phase III Clinical Trials
Philip J Mease¹, Alvin F Wells², Jürgen Wollenhaupt³, Stephen Hall⁴, Filip van Den Bosch⁵, Eric Lespessailles⁶, Melissa McIlraith⁷, Dianne Nguyen⁷, Lichen Teng⁷ and Christopher J Edwards⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Rheumatology & Immunotherapy Center, Franklin, WI, ³Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁴Monash University, CabriniHealth, Melbourne, Australia, ⁵UZ Gent, Gent, Belgium, ⁶University of Orléans, Orléans, France, ⁷Celgene Corporation, Summit, NJ, ⁸University Hospital Southampton, Southampton, United Kingdom
Background/Purpose: Improving and preserving patient (pt) physical function is an important goal in managing psoriatic arthritis (PsA). Apremilast (APR) has been shown to improve signs…
Abstract Number: 1741 • 2016 ACR/ARHP Annual Meeting
Patients with Active Psoriatic Arthritis Achieving Minimal Disease Activity with Secukinumab Treatment Demonstrate Sustained Improvement of Function and Quality of Life
Laura C. Coates¹, Philip J Mease², Laure Gossec³, Bruce Kirkham⁴, Lawrence Rasouliyan⁵, Shephard Mpofu⁶, Steffen Jugl⁶, Chetan Karyekar⁷ and Kunal Gandhi⁷, ¹University of Leeds, Leeds, United Kingdom, ²Rheumatology and Internal Medicine, Swedish Medical Center and University of Washington, Seattle, WA, ³Rheumatology Department, Hôpital Pitié Salpêtrière, Paris 06 University, Paris, France, ⁴Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁵RTI Health Solutions, Barcelona, Spain, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, a fully human anti–IL-17A monoclonal antibody, previously demonstrated higher minimal disease activity (MDA)1 response rates and sustained improvements in patient reported outcomes2 among…
Abstract Number: 1742 • 2016 ACR/ARHP Annual Meeting
Effect of DMARD Therapies on NSAID Intake, Quality of Life, and Physical Functioning in Patients with Ankylosing Spondylitis
Gulay KINIKLI¹, Gizem Irem KINIKLI², Sevilay KARAHAN³, Ayten YUKSEK⁴, Askin ATES⁵ and Murat TURGAY⁶, ¹Department of Rheumatology, Ankara University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ²Hacettepe University Faculty of Health Sciences Department of Physiotherapy and Rehabilitation, Ankara, Turkey, ³Hacettepe University, Faculty of Medicine, Department of Biostatistics, Ankara, Turkey, ⁴Department of Rheumatology, Ankara Ibn_i Sina Hospital, Department of Rheumatology, Ankara, Turkey, ⁵Ankara University, Faculty of Medicine, Department of Internal Medicine, Rheumatology, Ankara, Turkey, ⁶Ankara University, Faculty of Medicine, Department of Internal Medicine, Rheumatology,, Ankara, Turkey
Background/Purpose: Conventional treatments include NSAID and physiotherapy remain the mainstay of treatment in Ankylosing Spondylitis (AS). After the failure of conventional therapy, DMARD therapies are…
Abstract Number: 1743 • 2016 ACR/ARHP Annual Meeting
Prevalence of Inflammatory Neck Pain in a Cohort of Patients with Psoriatic Arthritis and Its Association with Clinical and Radiographic Features
Osvaldo Luis Cerda, Margarita Landi, Cecilia Zaffarana, Josefina Gallino Yanzi, Emilce Schneeberger and Gustavo Citera, Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: Cervical inflammatory pain is very common and rarely studied in patients with Psoriatic Arthritis (PsA). The purpose of our study was to evaluate the…
Abstract Number: 1744 • 2016 ACR/ARHP Annual Meeting
Expression of C1q By Podocytes at Late Stages of Proliferative Lupus Glomerulonephritis
Hongyang Wang¹, Ou Jin², Niansheng Yang³, Chao Dai¹, Sun-sang Sung¹, Felicia Gaskin⁴ and Shu Man Fu⁵, ¹Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, ²Rheumatology, Sun Yat-sen University Third Affiliated Hospital, Guangzhou, China, ³Rheumatology, Sun Yat-sen University First Affiliated Hospital, Guangzhou, China, ⁴Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA, ⁵Department of Medicine, University of Virginia, Charlottesville, VA
Background/Purpose: In NZM2328 (NZM), a mouse model of proliferative lupus glomerulonephritis (GN), lupus GN can be categorized to four stages, i.e. normal, acute GN (aGN),…
Abstract Number: 1745 • 2016 ACR/ARHP Annual Meeting
Disturbance of Renal Circadian Rhythm in Lupus Nephritis
Rakesh Mishra¹, Ramalingam Bethunaickan², Weijia Zhang³ and Anne Davidson⁴, ¹Feinstein Institute, Manhasset, NY, ²Autoimmune and musculosketal diseases, Feinstein Institute for Medical Research, Manhasset, NY, ³Nephrology, Mount Sinai School of Medicine, New York, NY, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Circadian rhythm is a universal phenomenon that allows organisms to anticipate and respond to changes in their environment by regulating sleep and feeding patterns,…
Abstract Number: 1746 • 2016 ACR/ARHP Annual Meeting
Immune Complex-Induced IL-6 Production By Lupus Prone Mesangial Cells Is Mediated By Neuraminidase Activity
Tamara K. Nowling¹, Kamala Sundararaj² and Leah Siskind³, ¹Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Pharmacology and Toxicology, University of Louisville, Louisville, KY
Background/Purpose: We made the novel observation that glycosphingolipid (GSL) levels and neuraminidase (NEU) (an enzyme that mediates GSL catabolism) activity/expression are altered in the kidneys…
Abstract Number: 1747 • 2016 ACR/ARHP Annual Meeting
Dissecting the Role of Single Complement Deficiencies in a Novel Model for Apoptotic Cell-Induced Lupus
Lucrezia Colonna¹, Clayton J. Sontheimer², Lena M. Tanaka³, Kelly L. Hudkins⁴, Charles E. Alpers⁴, Keith B. Elkon¹ and YuFeng Peng³, ¹Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ²Pediatric Rheumatology, University of Washington, Seattle, WA, ³Division of Rheumatology, University of Washington, Seattle, WA, ⁴Pathology, University of Washington, Seattle, WA
Background/Purpose: The role of complement in Systemic Lupus Erythematosus (SLE) is complex as complement deficiencies in early components of the classical pathway cause lupus with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].